SCHEMBL1714464

SCHEMBL1714464

CCCCC1=NC(=Cc2c[nH]c3ncc(Cl)cc23)C(=O)N1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.34
▸ BRAF P15056 3/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ BMPR1B O00238 1/20 0.32
▸ PLK4 O00444 1/20 0.32
▸ PIR O00625 1/20 0.32
▸ AURKA O14965 1/20 0.32
▸ DCLK1 O15075 1/20 0.32
▸ EPHB6 O15197 1/20 0.32
▸ RIPK2 O43353 1/20 0.32
▸ STK16 O75716 1/20 0.32
▸ OXSR1 O95747 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ RAF1 P04049 1/20 0.32
▸ LCK P06239 1/20 0.32
▸ FYN P06241 1/20 0.32
▸ FES P07332 1/20 0.32
▸ CSF1R P07333 1/20 0.32
▸ YES1 P07947 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714461 1.00 CYP3A4 (0.34) CYP3A4BRAFJAK2BMPR1BPLK4
SCHEMBL1714309 0.85 CYP3A4 (0.34) CYP3A4JAK2MEN1LMNAPABPC1
SCHEMBL1714307 0.85 CYP3A4 (0.34) CYP3A4JAK2MEN1LMNAPABPC1
SCHEMBL1714021 0.82 JAK2 (0.37) CYP3A4BRAFJAK2MEN1LMNA
SCHEMBL1714019 0.82 JAK2 (0.37) CYP3A4BRAFJAK2MEN1LMNA
SCHEMBL1714273 0.82 KMT2A (0.44) MAP4K4HIPK2KMT2A
SCHEMBL1714276 0.82 KMT2A (0.44) MAP4K4HIPK2KMT2A
SCHEMBL1714259 0.80 JAK2 (0.34) CYP3A4BRAFJAK2BMPR1BPLK4
SCHEMBL1714261 0.80 JAK2 (0.34) CYP3A4BRAFJAK2BMPR1BPLK4
SCHEMBL1714114 0.79 JAK2 (0.35) CYP3A4JAK2MEN1LMNAPABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 — — US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 — — EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 CYP3A4 1944/4885BRAF 280/4885JAK2 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback